Interventions for treating cholestasis in pregnancy

Ursodeoxycholic acid for intrahepatic cholestasis of pregnancy: good for the mother, not bad for the baby

“…Although these findings had previously been reported, the sample sizes were small, heterogeneity of study design hampered interpretation and a previous meta-analysis failed to demonstrate a significant effect 3. With any pharmacological intervention in pregnancy, safety concerns abound and clinicians may not be willing to prescribe medication if any uncertainty about its safety or efficacy exists.…”

Ursodeoxycholic acid for intrahepatic cholestasis of pregnancy: good for the mother, not bad for the baby

“…Although these findings had previously been reported, the sample sizes were small, heterogeneity of study design hampered interpretation and a previous meta-analysis failed to demonstrate a significant effect 3. With any pharmacological intervention in pregnancy, safety concerns abound and clinicians may not be willing to prescribe medication if any uncertainty about its safety or efficacy exists.…”

Systematic review and meta-analysis: Evaluating the influence of intrahepatic cholestasis of pregnancy on obstetric and neonatal outcomes

“…ICP is a serious condition that can have significant negative effects on both maternal and neonatal outcomes through various mechanisms [ 13 , 14 , 38 , 39 ]. We have organized our discussion into two distinct segments: one addressing the findings derived from the systematic review and another from the meta-analysis, offering clarity and coherence for the reader.…”

Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy

“…UDCA is the most efficient drug to cure ICP, but there is no sufficient evidence to recommend UDCA alone or in combination with other drugs in treating women with ICP. Burrows et al [ 28 ] reported that no evidence of positive effects for patients with ICP from taking UDCA. More researches were needed.…”

“…In a previous meta-analysis, UDCA was effective in reducing pruritus and decreasing liver test results in patients with ICP. [ 15 ] But Burrows et al [ 28 ] reported UDCA was not proved to be significantly better than placebo in improving pruritus. We planned to dichotomise pruritus after test of intervention as “improvers” and “nonimprovers.” The result demonstrated a greater support for treatment of UDCA compared with controls in improving pruritus scores, which was coincident with the reports.…”

Ursodeoxycholic acid for intrahepatic cholestasis of pregnancy: good for the mother, not bad for the baby

“…Although these findings had previously been reported, the sample sizes were small, heterogeneity of study design hampered interpretation and a previous meta-analysis failed to demonstrate a significant effect 3. With any pharmacological intervention in pregnancy, safety concerns abound and clinicians may not be willing to prescribe medication if any uncertainty about its safety or efficacy exists.…”

Systematic review and meta-analysis: Evaluating the influence of intrahepatic cholestasis of pregnancy on obstetric and neonatal outcomes

“…ICP is a serious condition that can have significant negative effects on both maternal and neonatal outcomes through various mechanisms [ 13 , 14 , 38 , 39 ]. We have organized our discussion into two distinct segments: one addressing the findings derived from the systematic review and another from the meta-analysis, offering clarity and coherence for the reader.…”

Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy

“…UDCA is the most efficient drug to cure ICP, but there is no sufficient evidence to recommend UDCA alone or in combination with other drugs in treating women with ICP. Burrows et al [ 28 ] reported that no evidence of positive effects for patients with ICP from taking UDCA. More researches were needed.…”

“…In a previous meta-analysis, UDCA was effective in reducing pruritus and decreasing liver test results in patients with ICP. [ 15 ] But Burrows et al [ 28 ] reported UDCA was not proved to be significantly better than placebo in improving pruritus. We planned to dichotomise pruritus after test of intervention as “improvers” and “nonimprovers.” The result demonstrated a greater support for treatment of UDCA compared with controls in improving pruritus scores, which was coincident with the reports.…”

Ursodeoxycholic acid for intrahepatic cholestasis of pregnancy: good for the mother, not bad for the baby

“…Although these findings had previously been reported, the sample sizes were small, heterogeneity of study design hampered interpretation and a previous meta-analysis failed to demonstrate a significant effect 3. With any pharmacological intervention in pregnancy, safety concerns abound and clinicians may not be willing to prescribe medication if any uncertainty about its safety or efficacy exists.…”

Systematic review and meta-analysis: Evaluating the influence of intrahepatic cholestasis of pregnancy on obstetric and neonatal outcomes

“…ICP is a serious condition that can have significant negative effects on both maternal and neonatal outcomes through various mechanisms [ 13 , 14 , 38 , 39 ]. We have organized our discussion into two distinct segments: one addressing the findings derived from the systematic review and another from the meta-analysis, offering clarity and coherence for the reader.…”

Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy

“…UDCA is the most efficient drug to cure ICP, but there is no sufficient evidence to recommend UDCA alone or in combination with other drugs in treating women with ICP. Burrows et al [ 28 ] reported that no evidence of positive effects for patients with ICP from taking UDCA. More researches were needed.…”

“…In a previous meta-analysis, UDCA was effective in reducing pruritus and decreasing liver test results in patients with ICP. [ 15 ] But Burrows et al [ 28 ] reported UDCA was not proved to be significantly better than placebo in improving pruritus. We planned to dichotomise pruritus after test of intervention as “improvers” and “nonimprovers.” The result demonstrated a greater support for treatment of UDCA compared with controls in improving pruritus scores, which was coincident with the reports.…”